WO2013167989A3 - Compositions et méthodes de traitement de troubles neurologiques - Google Patents

Compositions et méthodes de traitement de troubles neurologiques Download PDF

Info

Publication number
WO2013167989A3
WO2013167989A3 PCT/IB2013/050801 IB2013050801W WO2013167989A3 WO 2013167989 A3 WO2013167989 A3 WO 2013167989A3 IB 2013050801 W IB2013050801 W IB 2013050801W WO 2013167989 A3 WO2013167989 A3 WO 2013167989A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
neurological disorders
compounds
Prior art date
Application number
PCT/IB2013/050801
Other languages
English (en)
Other versions
WO2013167989A2 (fr
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Priority to AU2013257710A priority Critical patent/AU2013257710B2/en
Priority to EP13788559.6A priority patent/EP2882427A2/fr
Priority to CN201380030658.0A priority patent/CN104797568A/zh
Priority to JP2015510895A priority patent/JP2015533114A/ja
Priority to CA2872976A priority patent/CA2872976A1/fr
Priority to SG11201407310TA priority patent/SG11201407310TA/en
Publication of WO2013167989A2 publication Critical patent/WO2013167989A2/fr
Priority to ZA2014/08061A priority patent/ZA201408061B/en
Publication of WO2013167989A3 publication Critical patent/WO2013167989A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des composés de formule I ou leurs sels pharmaceutiquement acceptables, ainsi que leurs formes polymorphes, leurs solvates, leurs énantiomères, leurs stéréoisomères et leurs hydrates. Elle concerne des compositions pharmaceutiques comprenant une quantité efficace de composés de formule I; et des méthodes de traitement ou de prévention de troubles neurologiques. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, sous forme de sirop ou d'injection. Ces compositions peuvent être utilisées pour traiter l'épilepsie, le trouble bipolaire, la migraine, la schizophrénie, la dépression, la maladie d'Alzheimer, le cancer, le VIH et la polypose adénomateuse familiale.
PCT/IB2013/050801 2012-05-08 2013-01-30 Compositions et méthodes de traitement de troubles neurologiques WO2013167989A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2013257710A AU2013257710B2 (en) 2012-05-08 2013-01-30 Compositions and methods for the treatment of neurological disorders
EP13788559.6A EP2882427A2 (fr) 2012-05-08 2013-01-30 Compositions et méthodes de traitement de troubles neurologiques
CN201380030658.0A CN104797568A (zh) 2012-05-08 2013-01-30 用于治疗神经障碍的组合物和方法
JP2015510895A JP2015533114A (ja) 2012-05-08 2013-01-30 神経疾患の治療のための組成物及び方法
CA2872976A CA2872976A1 (fr) 2012-05-08 2013-01-30 Compositions et methodes de traitement de troubles neurologiques
SG11201407310TA SG11201407310TA (en) 2012-05-08 2013-01-30 Compositions and methods for the treatment of neurological disorders
ZA2014/08061A ZA201408061B (en) 2012-05-08 2014-11-04 Compositions and methods for the treatment of neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1789/CHE/2012 2012-05-08
IN1789CH2012 2012-05-08

Publications (2)

Publication Number Publication Date
WO2013167989A2 WO2013167989A2 (fr) 2013-11-14
WO2013167989A3 true WO2013167989A3 (fr) 2016-08-25

Family

ID=54193688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050801 WO2013167989A2 (fr) 2012-05-08 2013-01-30 Compositions et méthodes de traitement de troubles neurologiques

Country Status (8)

Country Link
EP (1) EP2882427A2 (fr)
JP (1) JP2015533114A (fr)
CN (1) CN104797568A (fr)
AU (1) AU2013257710B2 (fr)
CA (1) CA2872976A1 (fr)
SG (1) SG11201407310TA (fr)
WO (1) WO2013167989A2 (fr)
ZA (1) ZA201408061B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873094A1 (fr) * 2012-05-07 2013-11-14 Cellixbio Private Limited Promedicaments d'agents antiplaquettaires
WO2014006529A2 (fr) * 2012-07-03 2014-01-09 Mahesh Kandula Compositions et méthodes de traitement de la douleur modérée à aiguë
CN114276516B (zh) * 2022-01-14 2022-11-18 浙江佳人新材料有限公司 一种以废旧纺织品化学法再生工艺的副产物制备硬质聚氨酯泡沫的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066920A1 (fr) * 1998-06-22 1999-12-29 American Biogenetic Sciences, Inc. Utilisation d'un analogue d'acide valproique dans le traitement et la prevention de migraine et de maladies affectives
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IT1190133B (it) * 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3726945A1 (de) * 1987-08-13 1989-02-23 Dietl Hans L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
CN1187813A (zh) * 1995-05-01 1998-07-15 斯科舍集团有限公司 作为生物活性化合物的脂肪酸酯
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CN101619040B (zh) * 2008-07-04 2012-05-09 中国科学院上海药物研究所 阿扑啡类化合物、其药物组合物及其用途
EP2364304A1 (fr) * 2008-11-07 2011-09-14 ISTITUTO BIOCHIMICO NAZIONALE SAVIO s.r.l. Dérivés de l'acide alpha-lipoïque et leur utilisation dans la préparation de médicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066920A1 (fr) * 1998-06-22 1999-12-29 American Biogenetic Sciences, Inc. Utilisation d'un analogue d'acide valproique dans le traitement et la prevention de migraine et de maladies affectives
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee

Also Published As

Publication number Publication date
CN104797568A (zh) 2015-07-22
ZA201408061B (en) 2016-04-28
WO2013167989A2 (fr) 2013-11-14
AU2013257710B2 (en) 2016-10-20
EP2882427A2 (fr) 2015-06-17
AU2013257710A1 (en) 2014-11-27
SG11201407310TA (en) 2014-12-30
CA2872976A1 (fr) 2013-11-14
JP2015533114A (ja) 2015-11-19

Similar Documents

Publication Publication Date Title
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
WO2014031438A3 (fr) Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
MX336966B (es) Novedosos derivados y su uso en el tratamiento de transtornos neurologicos.
WO2013175376A3 (fr) Compositions et méthodes de traitement de la douleur locale
WO2013175377A3 (fr) Compositions et méthodes pour le traitement de la mucosite
WO2014087367A3 (fr) Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
WO2014141057A3 (fr) Compositions et méthodes de traitement du cancer
WO2014174425A3 (fr) Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
WO2013168006A3 (fr) Compositions et méthodes de traitement de la douleur locale
WO2013167989A3 (fr) Compositions et méthodes de traitement de troubles neurologiques
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
WO2014006529A3 (fr) Compositions et méthodes de traitement de la douleur modérée à aiguë
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2013167986A3 (fr) Compositions et méthodes de traitement de l'épilepsie
WO2014068459A3 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2014068461A3 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
WO2014006528A3 (fr) Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2017208088A3 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
WO2014122621A3 (fr) Compositions et procédés pour le traitement d'états métaboliques et de maladies neuromusculaires
WO2015028976A3 (fr) Composés et méthodes de traitement de maladies inflammatoires

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2872976

Country of ref document: CA

Ref document number: 2015510895

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013788559

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257710

Country of ref document: AU

Date of ref document: 20130130

Kind code of ref document: A